{
    "ticker": "CTSO",
    "name": "Cytosorbents Corporation",
    "description": "Cytosorbents Corporation is a medical technology company focused on developing and commercializing innovative blood purification therapies. Founded in 1998 and headquartered in Monmouth Junction, New Jersey, the company is at the forefront of addressing critical unmet medical needs in the management of severe inflammatory conditions and life-threatening infections. Cytosorbents' flagship product, CytoSorb, is an FDA-cleared and CE-marked therapy that removes excess cytokines and other inflammatory mediators from the blood, providing a novel approach to treating conditions such as sepsis, trauma, and cardiac surgery. The company also develops other products aimed at enhancing patient outcomes in critical care settings. With a commitment to scientific research and clinical validation, Cytosorbents collaborates with leading medical institutions and researchers worldwide to further its mission of improving patient care and outcomes. The company is also expanding its product portfolio to include additional blood purification technologies to address a range of medical challenges, thereby positioning itself as a leader in the field of blood management and critical care.",
    "industry": [
        "Medical Technology",
        "Healthcare"
    ],
    "headquarters": "Monmouth Junction, New Jersey, USA",
    "founded": "1998",
    "website": "https://www.cytosorbents.com",
    "ceo": "Philip C. W. van der Veen",
    "social_media": {
        "twitter": "https://twitter.com/cytosorbents",
        "linkedin": "https://www.linkedin.com/company/cytosorbents/"
    },
    "investor_relations": "https://investors.cytosorbents.com",
    "key_executives": [
        {
            "name": "Philip C. W. van der Veen",
            "position": "CEO"
        },
        {
            "name": "Kurt A. Kahn",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Blood Purification",
            "products": [
                "CytoSorb"
            ]
        },
        {
            "category": "Critical Care",
            "products": [
                "HemoDefend"
            ]
        }
    ],
    "seo": {
        "meta_title": "Cytosorbents Corporation | Innovative Blood Purification Therapies",
        "meta_description": "Explore Cytosorbents Corporation's groundbreaking technologies in blood purification and critical care. Discover how Cytosorbents is revolutionizing patient treatment.",
        "keywords": [
            "Cytosorbents",
            "Blood Purification",
            "Medical Technology",
            "Healthcare",
            "CytoSorb",
            "Critical Care"
        ]
    },
    "faq": [
        {
            "question": "What is Cytosorbents known for?",
            "answer": "Cytosorbents is known for its innovative blood purification therapies, particularly the CytoSorb device."
        },
        {
            "question": "Who is the CEO of Cytosorbents?",
            "answer": "Philip C. W. van der Veen is the CEO of Cytosorbents Corporation."
        },
        {
            "question": "Where is Cytosorbents headquartered?",
            "answer": "Cytosorbents is headquartered in Monmouth Junction, New Jersey, USA."
        },
        {
            "question": "What are Cytosorbents' main products?",
            "answer": "Cytosorbents' main product is CytoSorb, a blood purification therapy used in critical care medicine."
        },
        {
            "question": "When was Cytosorbents founded?",
            "answer": "Cytosorbents was founded in 1998."
        }
    ],
    "competitors": [
        "CRMD",
        "NXGN",
        "PSTG"
    ],
    "related_stocks": [
        "AAPL",
        "MSFT",
        "AMGN",
        "GILD"
    ]
}